For example, a recent national audit of stroke care in Australia found that only 67% of hospitalized patients received stroke unit care (i.e., care in an organizational unit characterized by co-located beds within a geographically defined unit staffed by a multidisciplinary team with a special interest and training in stroke and/or rehabilitation), and only 13% of those with acute ischemic stroke (AIS) received thrombolytic treatment with intravenous recombinant tissue plasminogen activator (rtPA) [3], both of which have been shown to improve outcomes [6, 7]. This evidence concerns the gene PLAT and Stroke.